These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 21963773)
1. In vivo antitumor effect of cromolyn in PEGylated liposomes for pancreatic cancer. Kim CE; Lim SK; Kim JS J Control Release; 2012 Jan; 157(2):190-5. PubMed ID: 21963773 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models. Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116 [TBL] [Abstract][Full Text] [Related]
3. Interstitial chemotherapy with ricin-loaded thermosensitive hydrogel in pancreatic cancer xenograft. Chen ZK; Lin LW; Weng XH; Xue ES; Lin YH Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):418-23. PubMed ID: 19666413 [TBL] [Abstract][Full Text] [Related]
4. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. Arumugam T; Ramachandran V; Logsdon CD J Natl Cancer Inst; 2006 Dec; 98(24):1806-18. PubMed ID: 17179482 [TBL] [Abstract][Full Text] [Related]
5. The bisphosphonate incadronate inhibits intraperitoneal dissemination in an in vivo pancreatic cancer model. Takiguchi S; Nishino Y; Inoue K; Ikeda M; Kataoka Y; Matsusue K; Nishiyama K; Iguchi H Oncol Rep; 2012 Jul; 28(1):111-6. PubMed ID: 22484715 [TBL] [Abstract][Full Text] [Related]
6. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes. Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877 [TBL] [Abstract][Full Text] [Related]
7. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model. Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811 [TBL] [Abstract][Full Text] [Related]
8. Designing and developing S100P inhibitor 5-methyl cromolyn for pancreatic cancer therapy. Arumugam T; Ramachandran V; Sun D; Peng Z; Pal A; Maxwell DS; Bornmann WG; Logsdon CD Mol Cancer Ther; 2013 May; 12(5):654-62. PubMed ID: 23303403 [TBL] [Abstract][Full Text] [Related]
9. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Dadashzadeh S; Vali AM; Rezaie M Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511 [TBL] [Abstract][Full Text] [Related]
10. A novel combination therapy with arsenic trioxide and parthenolide against pancreatic cancer cells. Wang W; Adachi M; Zhang R; Zhou J; Zhu D Pancreas; 2009 May; 38(4):e114-23. PubMed ID: 19342982 [TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Stover TC; Sharma A; Robertson GP; Kester M Clin Cancer Res; 2005 May; 11(9):3465-74. PubMed ID: 15867249 [TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models. Kaminskas LM; McLeod VM; Kelly BD; Cullinane C; Sberna G; Williamson M; Boyd BJ; Owen DJ; Porter CJ Mol Pharm; 2012 Mar; 9(3):422-32. PubMed ID: 22233281 [TBL] [Abstract][Full Text] [Related]
13. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan. Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756 [TBL] [Abstract][Full Text] [Related]
14. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718 [TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856 [TBL] [Abstract][Full Text] [Related]
16. Effective targeted chemotherapy using AEZS-108 (AN-152) for LHRH receptor-positive pancreatic cancers. Gründker C; Ernst J; Reutter MD; Ghadimi BM; Emons G Oncol Rep; 2011 Sep; 26(3):629-35. PubMed ID: 21667032 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells. Nambiar D; Prajapati V; Agarwal R; Singh RP Cancer Lett; 2013 Jun; 334(1):109-17. PubMed ID: 23022268 [TBL] [Abstract][Full Text] [Related]
18. Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model. Ding X; Zhou X; Zhang H; Qing J; Qiang H; Zhou G Cancer Chemother Pharmacol; 2012 Jan; 69(1):253-61. PubMed ID: 21713446 [TBL] [Abstract][Full Text] [Related]
19. Antitumor and apoptosis-promoting properties of emodin, an anthraquinone derivative from Rheum officinale Baill, against pancreatic cancer in mice via inhibition of Akt activation. Wei WT; Chen H; Ni ZL; Liu HB; Tong HF; Fan L; Liu A; Qiu MX; Liu DL; Guo HC; Wang ZH; Lin SZ Int J Oncol; 2011 Dec; 39(6):1381-90. PubMed ID: 21805032 [TBL] [Abstract][Full Text] [Related]
20. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]